CNBC · Finance · 2026-08-20
Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says
Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley. Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says
Read original on CNBC Get the app
Licensed summary · LicensedSummary
Related briefs
- Why Walmart’s results have investors so worried: 'One of the biggest misses in years'
- This fertility benefit business is set to boom. Buy the stock now, Wells Fargo says
- Bitcoin surges 11% in two days as Trump, crypto execs lead last ditch effort for Clarity Act
- Jim Cramer's top 10 things to watch in the stock market Thursday
- Treasury proposes low-cost investment rules for Trump Accounts